ABE1950
Anti-DBC1 Antibody
from rabbit
Synonym(s):
Cell cycle and apoptosis regulator protein 2, Cell division cycle and apoptosis regulator protein 2, DBIRD complex subunit KIAA1967, Deleted in breast cancer gene 1 protein, DBC-1, DBC.1, p30 DBC, DBC1
Select a Size
About This Item
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
technique(s)
ChIP: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CCAR2(57805)
General description
Immunogen
Application
Epigenetics & Nuclear Function
Nuclear Receptors
Western Blotting Analysis: A representative lot detected DBC1 in MDA-MB-231 cell lysate (Koyama, S., et al. (2010). BBRC. 392:357-362).
Immunoprecipitation Analysis: A representative lot immunoprecipitated DBC1 in HeLa cell lysate (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Immunocytochemistry Analysis: A representative lot detected DBC1 in MCF7 cells (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Immunocytochemistry Analysis: A representative lot detected DBC1 in MCF7 and T47D cells (Koyama, S., et al. (2010). BBRC. 392:357-362).
Immunohistochemistry Analysis: A representative lot detected DBC1 in ductal epithelium and adipose regions of human breast tissue sections (Hiraike, H., et al. (2010). British Journal of Cancer. 102:1061-1067).
Immunohistochemistry Analysis: A representative lot detected DBC1 in human breast cancer tissue (Hiraike, H., et al. (2011). Experimental and Therapeutic Medicane. 2:1105-1109).
Chromatin Immunoprecipitation (ChIP) Analysis: A representative lot detected DBC1 occupancy at the SIRT1 gene promoter region (1354–1902) known to be targeted by BRCA1 (Hiraike, H., et al. (2010). Br. J. Cancer. 102(6):1061-1067).
Biochem/physiol Actions
Physical form
Preparation Note
Analysis Note
Western Blotting Analysis: 2.0 µg/mL of this antibody detected DBC1 in 10 µg of MCF7 cell lysate.
Other Notes
Disclaimer
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.
Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service